# Christian Cobaugh

> Christian Cobaugh is a molecular biologist turned biotech operator who has spent more than 15 years at the frontier of genetic medicines. In January 2026 he became CEO of Alloy Genetic Medicines, the nucleic-acid division of Alloy Therapeutics, where he leads work on the AntiClastic cyclic nucleic acid platform for ASOs, siRNA, and other RNA therapeutics. He is best known for founding Vernal Biosciences, an mRNA contract manufacturer he built in Colchester, Vermont, on the premise that everyone who needs mRNA should be able to get it. Before Vernal he was the first scientist in the Alexion-Moderna mRNA partnership and held discovery, development, and manufacturing roles at Arcturus Therapeutics, CRISPR Therapeutics, Translate Bio, and Omega Therapeutics.

- **Role:** CEO of Alloy Genetic Medicines at Alloy Therapeutics
- **Organizations:** Alloy Therapeutics, Alloy Genetic Medicines, Vernal Biosciences, Omega Therapeutics, Translate Bio, CRISPR Therapeutics, Arcturus Therapeutics, Alexion Pharmaceuticals
- **From:** St. Louis, Missouri, United States
- **Nationality:** American
- **Education:** M.S., Molecular Pharmacology, Northwestern University, Ph.D., Cell and Molecular Biology, University of Texas at Austin
- **Known for:** Founding CEO of Vernal Biosciences, a Vermont-based mRNA CDMO built to democratize access to high-purity mRNA, First scientist recruited into the Alexion-Moderna mRNA partnership, Raised roughly $20-21 million in growth capital for Vernal Biosciences

## Career timeline

- **1999** — Earns master's in molecular pharmacology from Northwestern University
- **2007** — Completes PhD in cell and molecular biology at University of Texas at Austin
- **2013-2014** — Joins Alexion Pharmaceuticals; becomes the first scientist in the Alexion-Moderna mRNA partnership
- **2016-2020** — Holds mRNA discovery, process and manufacturing leadership roles at Arcturus Therapeutics, CRISPR Therapeutics, Translate Bio, and Omega Therapeutics
- **2021** — Founds Vernal Biosciences in Colchester, Vermont, with seed financing led by Alloy Therapeutics
- **2023** — Vernal raises roughly $20-21 million to expand mRNA manufacturing; team grows past 60
- **2025** — Steps back from Vernal CEO role to Chief Scientific Officer and board director as Jim Petrilla is named CEO
- **2026** — Appointed CEO of Alloy Genetic Medicines to lead the AntiClastic nucleic acid platform

## Achievements

- Founding CEO of Vernal Biosciences, a Vermont-based mRNA CDMO built to democratize access to high-purity mRNA
- First scientist recruited into the Alexion-Moderna mRNA partnership
- Raised roughly $20-21 million in growth capital for Vernal Biosciences
- Led discovery, development, and manufacturing teams across five leading genetic-medicine companies
- Appointed CEO of Alloy Genetic Medicines to commercialize the AntiClastic cyclic nucleic acid technology

## Latest updates

- **2026-01** — Named CEO of Alloy Genetic Medicines, leading the AntiClastic cyclic nucleic acid platform for RNA-based therapeutics.

## Links

- Website: https://alloytx.com
- LinkedIn: http://www.linkedin.com/in/christian-cobaugh
- Twitter/X: https://twitter.com/alloytx

---

Profile page: https://yespress.io/christian-cobaugh
Published by YesPress — https://yespress.io
Last updated: 2026-07-01